Inveterate deal-maker and former six-term congressman Jim Greenwood believes the biopharma industry should engage on drug pricing legislation with the newly Democratic-controlled US Congress and President-elect Joe Biden and perhaps concede to price inflation rebates in Medicare to avoid worse policies like international reference pricing.
Greenwood, who spent the last 15 years as president and CEO of the Biotechnology Innovation Organization, is now senior policy...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?